Added 1 month ago Drug news
Health Canada approves Taltz to treat adult patients with active ankylosing spondylitis .- Eli Lilly
Eli Lilly Canada announced that Health Canada approved Taltz (ixekizumab) on February 4, 2020, for the treatment of adult patients...
Added 2 months ago Drug news
FDA advisory committee does not recommend oxycodegol ( NKTR 181) as a treatment for chronic pain and the drug is withdrawn.- Nektar Therapeutics
Nektar Therapeutics issued a statement following a meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and...
Added 3 months ago Drug news
Amgen has announced that the FDA has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade (infliximab):...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over.
Added 10 years ago
This guideline provides recommendations based on current evidence for best practice in the assessment and management, in non-specialist settings, of adults with chronic non-malignant pain...
Added 6 years ago
No increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies.
Secukinumab (SEC), a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis (PsO), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
Added 2 years ago
Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis.
Objective: To investigate the regulatory effect of tumour necrosis factor (TNF) blockade with infliximab on the distribution of peripheral blood...
Added 4 years ago
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
Added 1 year ago
Overdiagnosis is the diagnosis of disease that will cause neither morbidity nor mortality during a patient’s lifetime. Doctors are trained to listen, examine, test, diagnose and treat patients, but we are not warned of the possible dangers of “diseases”, the diagnosis of which will not benefit the patient and may also lead to harm. I would argue that the Hippocratic oath, in particular “Primum non nocere” (first, do no harm) should be at the forefront of every clinician’s mind when seeing patients.
- Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- Registration required
- Subscription fee